Editorial
leading to adverse events and focus on the development of less traumatic pumps.
It is commonly agreed that a major part of the complications are related to device-induced effects on blood. On their way through the pump and its cannulae, blood components are subjected to strong influences that may either damage cells or proteins or enhance thrombogenesis. Although intensive research has been focused on blood damage, the underlying mechanisms are still not well understood in their entire complexity. This special issue thus addresses important aspects of blood damage in VADs. Most contributions evolved from presentations given at the European Society of Artificial Organs congress held in Rome in 2014, where the idea for the scope of this special issue emerged. Other experts were also recruited, making this issue an important contribution to current research in this field. This editorial summarizes these contributions and highlights the future challenges that should be addressed.
Summary of contents
Hemolysis, or damage to erythrocytes, has already been extensively investigated and is still one of the most important parameters to evaluate devices in terms of blood damage. Whereas the effects leading to lethal damage of erythrocytes are well investigated (9), Olia et al (10) and Poorkhalil et al (11) highlight a less known topic: the sublethal damage of erythrocytes. Olia et al summarize the current understanding of this topic in a review (10) . Poorkhalil et al suggest a numerical model that considers not only the breakdown of the erythrocyte cell membrane but also the release of hemoglobin through the functional membrane (11) . Another parameter that has important effects on blood damage is the roughness of the surface in contact with blood. According to the report of Watanabe et al (12) published in this issue, the ratio of the surface roughness to the flow scale is an additional parameter to take into account for evaluation of shearinduced hemolysis.
Usually, the prediction of hemolysis in blood pumps is estimated based on numerical models implemented into computational fluid dynamics (CFD) analyses. These hemolysis models are derived from in vitro experiments using mostly laminar shearing devices (13, 14) and are incorporated in CFD in a Eulerian or Lagrangian manner. In this special issue, Gesenhues et al (15) present a comparison of a strainbased and a stress-based approach with experimental data for a centrifugal pump, indicating significant differences between these methods. The pump model originates from an FDA critical path initiative to investigate the use of CFD in the DOI: 10.5301/ijao.5000506
Introduction
During the past few decades, survival rates with ventricular assist devices (VADs) have increased substantially (1) mainly due to the rapid development of new technologies. The first Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart failure (REMATCH) trial demonstrated a survival advantage of pulsatile VADs over optimal medical treatment (2) . Then, in the REMATCH II trial conducted 10 years later, a rotary blood pump (Thoratec Heartmate II; HM II) outperformed its pulsatile predecessor Heartmate XVE (3). Today, the 1-year survival rate with these continuous-flow pumps reached 85%, VAD therapy has become a standard treatment option (4) and is increasingly used as an alternative to heart transplantation.
However, despite this essential progress, new large-scale prospective studies have also indicated the limits of this therapy. The ENDURANCE trial for destination therapy discovered high incidences of bleeding, infection, and stroke (5) . The REVIVE-IT study, which was designed to evaluate the benefit of VAD therapy in less sick, ambulatory heart failure patients, had to be suspended by the principal investigators due to concerns regarding clinical equipoise because of the high incidence of adverse events (6) . Also, INTERMACS data prove the occurrence of a high number of severe complications (1) . A large proportion of these complications is related to the limited hemocompatibility of these devices. Even with new and promising technologies, which have come onto the market recently, the complication rate does not seem to decrease substantially despite huge efforts on the part of VAD companies and the scientific community (7) . Consequently, the clinical benefit and the cost efficiency of VAD therapy remain limited (8) . If the acceptance of rotary blood pumps shall continue to grow in the future, the adverse event rate needs to be drastically reduced in order to increase life expectancy, improve quality of life and decrease the costs of the therapy. Future research efforts need to clarify the causes development and evaluation of blood damage of VADs, which acknowledges the importance of this field.
Turbulent effects also contribute to hemolysis: when comparing a laminar and a turbulent capillary flow with equal wall shear stresses, the turbulent one causes more damage to erythrocytes (16) . However, the direct causes have not been identified so far and no numerical model of turbulent damage exists. In this issue, Goubergrits et al (17) suggest a new approach to simulate turbulent blood damage. Turbulent pathlines were generated from Reynolds Averaged Navier Stokes-CFD flow fields with a stochastic scheme and a standard power law model is used to calculate hemolysis. Such an approach is an important step in the direction of more reliable numerical blood damage prediction.
Besides these important contributions, further effects should be addressed in the investigations of hemolysis in blood pumps: cell migration and blood cell separation -as known from the Fåhraeus-Lindqvist effect -should be considered in blood damage modeling. Such effects might play a role in the small gaps of blood pumps (18) . Consequently, high shear stresses in these regions might not contribute to hemolysis as strongly as they would in the main flow path.
Another important parameter necessary to estimate blood trauma is the exposure time, hence, residence times within the devices must be carefully observed. Since prolonged contact with artificial material leads to platelet adhesion and thrombus formation, this parameter is also needed to evaluate the thrombogenic potential of artificial organs. However, the processes leading to a thrombus formation are multifactorial and highly complex and thus, very difficult to predict. Blood pump design commonly aims at a good washout with moderate wall shear stresses and low residence times, although no clear thresholds are defined. Therefore, investigations like the one in this issue by Maruyama et al (19) are of major importance: the authors performed in vitro tests to detect thrombogenesis in bovine blood depending on the shear stress level and to measure blood coagulability using a rheometer. In rotary blood pumps mainly 2 different types of thrombus may develop depending on local flow conditions. A soft, red thrombus forms quickly and in areas of low flow, the white thrombus is rather hard; it takes more time to form in areas of high shear rates with the help of von Willebrand factor nets, as described by Casa, Deaton and Ku (20) . In this issue, Hastings et al (21) report in vitro results of thrombus formations in an extracorporeal rotary blood pump. In addition, Consolo et al (22) propose a microfluidic approach to assess the blood's thrombogenic risk in flow conditions comparable to those in blood pumps. They report in vitro results thereby proving the feasibility of this technique. These contributions highlight that more research focused on thrombogenesis is required to identify the underlying causes so as to be able to optimize pumps.
When considering current know-how and ongoing research in the field of blood damage and thrombogenesis in VADs, it becomes evident that there is space for improvements and innovations regarding the technology of these devices. In this issue, Thamsen et al (23) present a CFD study which suggests a 2-stage pump design to reduce shear rate and, as a consequence, to substantially reduce blood trauma.
Future perspectives
The link between blood damage and the observed adverse events, however, remains an unanswered question. Moreover, inherent challenges posed by the current technology of rotary blood pumps need to be addressed. These pumps are optimized for a specific operating point -achieving the best hydrodynamic and hemocompatible performance at only this point. However, the clinical requirements are not consistent with this circumstance: the desire for a large flow pulsatility results in a wide range of operating points even in 1 cardiac cycle. Additionally, the same devices are used for partial and full support, for male or female patients (24) and even for small children (25) with varying success. This leads to a challenge for rotary blood pump technology and the question arises whether better engineered pumps with improved hemocompatibility under a large variety of clinical boundary conditions will be realizable or if we have already reached the limits of this technology.
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